| The ins and outs of serine and glycine metabolism in cancer SL Geeraerts, E Heylen, K De Keersmaecker, KR Kampen Nature metabolism 3 (2), 131-141, 2021 | 141 | 2021 |
| Repurposing the antidepressant sertraline as SHMT inhibitor to suppress serine/glycine synthesis–addicted breast tumor growth SL Geeraerts, KR Kampen, G Rinaldi, P Gupta, M Planque, N Louros, ... Molecular cancer therapeutics 20 (1), 50-63, 2021 | 62 | 2021 |
| Transcription factor NKX2–1 drives serine and glycine synthesis addiction in cancer E Heylen, P Verstraete, L Van Aerschot, SL Geeraerts, T Venken, ... British journal of cancer 128 (10), 1862-1878, 2023 | 14 | 2023 |
| Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer A Sánchez-Castillo, E Heylen, J Hounjet, KG Savelkouls, NG Lieuwes, ... British Journal of Cancer 130 (4), 568-584, 2024 | 6 | 2024 |
| The ins and outs of serine and glycine metabolism in cancer. Nat Metab 3: 131–141 SL Geeraerts, E Heylen, K De Keersmaecker, KR Kampen | 5 | 2021 |
| Serine/glycine synthesis addiction in cancer and resulting therapeutic opportunities KR Kampen, E Heylen, P Verstraete, SL Geeraerts, J Hounjet, B Cammue, ... 54th Conference of the European Metabolic Group (EMG), Location: Leuven, 2024 | | 2024 |
| TRANSCRIPTION FACTOR NKX2-1 PROTECTS T-ALL CELLS FROM DNA DAMAGE D Cabrerizo Granados, L Van Aerschot, K Timcheva, E Heylen, ... EHA 2024, Location: Madrid, 2024 | | 2024 |
| The transcription factor NKX2-1 protects T-ALL cells from DNA damage L Van Aerschot, D Cabrerizo Granados, P Verstraete, K Timcheva, ... Molecular aspects of normal and malignant hematopoiesis, Date: 2024/06/10 …, 2024 | | 2024 |
| 1866: Targeting serine/glycine metabolism improves radiotherapy response in Non-Small Cell Lung Cancer AS Castillo, E Heylen, J Hounjet, KG Savelkouls, NG Lieuwes, R Biemans, ... Radiotherapy and Oncology 194, S5217-S5220, 2024 | | 2024 |
| Sertraline synergizes with proteasome inhibition and deacetylase inhibition in ALL and lymphoma P Verstraete, K De Keersmaecker, E Heylen 6th workshop on Molecular aspects of normal and malignant hematopoiesis …, 2023 | | 2023 |
| Uncovering the role of the NKX2-1 transcription factor in T-ALL L Van Aerschot, K Timcheva, E Heylen, J Royaert, J Verbeeck, ... Oncoforum, Location: Gasthuisberg, KU Leuven, 2023 | | 2023 |
| Oncogenic drivers and therapeutic targeting of serine and glycine synthesis in cancer E Heylen, K De Keersmaecker, K Kampen | | 2023 |
| NKX2-1 DRIVES SERINE/GLYCINE SYNTHESIS ADDICTION IN CANCER E Heylen, S Geeraerts, L Van Aerschot, S Vereecke, J Verbeeck, ... EMBO Workshop Cancer immunometabolism, Date: 2021/11/29-2021/12/01, Location …, 2021 | | 2021 |
| Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation NG Kint, E Heylen, D Pepe, K De Keersmaecker, CM Verfaillie, ... Leukemia 34 (2), 651-655, 2020 | | 2020 |
| Carfilzomib treatment causes reticulocytosis by impairing terminal erythroid maturation in patients with multiple myeloma N Kint, E Heylen, K De Keersmaecker, C Verfaillie, M Delforge 24th Congress of the European Hematology Association, Date: 2019/06/13-2019 …, 2019 | | 2019 |
| PF570 CARFILZOMIB TREATMENT CAUSES RETICULOCYTOSIS BY IMPAIRING TERMINAL ERYTHROID MATURATION IN PATIENTS WITH MULTIPLE MYELOMA N Kint, E Heylen, K De Keersmaecker, C Verfaillie, M Delforge HemaSphere 3, 237, 2019 | | 2019 |
| Development of reticulocytosis through inhibition of terminal erythroid maturation by carfilzomib treatment in multiple myeloma N Kint, E Heylen, K De Keersmaecker, C Verfaillie, M Delforge Belgian Hematology Society-General Annual Meeting, Date: 2019/02/01-2019/02 …, 2019 | | 2019 |
| Proteasome Inhibition By Carfilzomib Impairs Terminal Erythroid Maturation and Causes Reticulocytosis in Patients with Multiple Myeloma N Kint, E Heylen, K De Keersmaecker, CM Verfaillie, M Delforge Blood 132, 1036, 2018 | | 2018 |
